NCT06371313

Brief Summary

This study is a cross-sectional study to explore the endocrine metabolism and inflammatory characteristics of the offspring of mothers with PCOS hyperandrogenism, in order to provide a theoretical basis for finding the cause of PCOS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 7, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 17, 2024

Completed
Last Updated

April 17, 2024

Status Verified

April 1, 2024

Enrollment Period

10 months

First QC Date

April 7, 2024

Last Update Submit

April 12, 2024

Conditions

Keywords

PCOSHyperandrogenemiaOffspringEndocrine and MetabolismInflammation

Outcome Measures

Primary Outcomes (10)

  • Testosterone

    Testosterone is one of the androgens, which can be used to assess androgen levels.

    Within one year after neonatal cord blood collection.

  • Androstenedione

    Androstenedione is one of the androgens, which can be used to assess androgen levels.

    Within one year after neonatal cord blood collection.

  • Dehydroepiandrosterone Sulfate

    Dehydroepiandrosterone Sulfate is one of the androgens, which can be used to assess androgen levels.

    Within one year after neonatal cord blood collection.

  • Sex Hormone Hinding Globulin

    Sex hormone-binding globulin, also known as testosterone-estradiol binding globulin, is a carrier of sex hormones and can reflect the level of sex hormones.

    Within one year after neonatal cord blood collection.

  • Free Androgen Index

    The free androgen index can reflect the biological activity of androgen.

    Within one year after neonatal cord blood collection.

  • Fasting Insulin

    Insulin is a hormone secreted by pancreatic beta cells that lowers blood glucose and produces energy metabolism. Its level can assist in the diagnosis of insulin resistance.

    Within one year after neonatal cord blood collection.

  • White Blood Cell Count

    The white blood cell count can assess the inflammatory status.

    Within six hours of neonatal cord blood collection.

  • Neutrophil Count

    Neutrophil count can be used to assess the inflammatory status.

    Within six hours of neonatal cord blood collection.

  • High-sensitivity C-reactive Protein

    High-sensitivity C-reactive protein can be used to assess the inflammatory status.

    Within six hours of neonatal cord blood collection.

  • Interleukin-6

    Interleukin (IL)-6 can be used to assess the inflammatory status.

    Within one year after neonatal cord blood collection.

Study Arms (2)

HA Group

Maternal hyperandrogenism of PCOS women with full-term singleton delivery were selected, and umbilical cord blood of their newborns was collected.

Control Group

Healthy pregnant women with full-term singleton delivery were randomly selected, and umbilical cord blood of their newborns was collected.

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The women selected into the study group were diagnosed with PCOS before pregnancy and were complicated with hyperandrogenism.

You may qualify if:

  • The diagnosis of polycystic ovary syndrome patients must meet the Rotterdam criteria.
  • Aged between 18 and 45 years old.
  • The gestational age of delivery is between 37 and 41 weeks of gestation.
  • Singleton pregnancy.
  • Signed informed consent form.

You may not qualify if:

  • Combined with reproductive organ malformations or chromosomal abnormalities.
  • Combined with chronic diseases such as diabetes and hypertension.
  • Combined with thyroid disease or other serious systemic diseases such as cardiovascular disease.
  • Multiple pregnancy.
  • Combined with congenital adrenal hyperplasia, Cushing\'s syndrome, hypertension Prolactinoma, and androgen-secreting tumor-related diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangdong Women and Children Hosptial

Guanzhou, Guangdong, 511400, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Cord Blood

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Li Li, M.D.

    Guangdong Women and Children Hospital

    STUDY CHAIR
  • Chen Yuan, Master

    Guangdong Women and Children Hosptial

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director, Institute of Women's and Children's Health

Study Record Dates

First Submitted

April 7, 2024

First Posted

April 17, 2024

Study Start

May 1, 2023

Primary Completion

March 5, 2024

Study Completion

March 5, 2024

Last Updated

April 17, 2024

Record last verified: 2024-04

Locations